102 related articles for article (PubMed ID: 25525854)
1. BMI variation increases recurrence risk in women with early-stage breast cancer.
Fedele P; Orlando L; Schiavone P; Quaranta A; Lapolla AM; De Pasquale M; Ardizzone A; Bria E; Sperduti I; Calvani N; Marino A; Caliolo C; Mazzoni E; Cinieri S
Future Oncol; 2014 Dec; 10(15):2459-68. PubMed ID: 25525854
[TBL] [Abstract][Full Text] [Related]
2. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
3. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
[TBL] [Abstract][Full Text] [Related]
4. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.
Bahl M; Ennis M; Tannock IF; Hux JE; Pritchard KI; Koo J; Goodwin PJ
Breast Cancer Res Treat; 2005 Nov; 94(2):135-44. PubMed ID: 16261412
[TBL] [Abstract][Full Text] [Related]
5. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing loco-regional relapse in older breast cancer patients treated with tumour resection and tamoxifen.
Kontos M; Allen DS; Agbaje OF; Hamed H; Fentiman IS
Eur J Surg Oncol; 2011 Dec; 37(12):1051-8. PubMed ID: 21843919
[TBL] [Abstract][Full Text] [Related]
7. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y
Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
11. Use of tamoxifen in pT1a-pT1b, pN0 breast cancer.
Livi L; Saieva C; Paiar F; Simontacchi G; Galardi A; De Luca Cardillo C; Mangoni M; Paoletti L; Ponticelli P; Biti GP
Eur J Surg Oncol; 2007 Apr; 33(3):271-5. PubMed ID: 16831531
[TBL] [Abstract][Full Text] [Related]
12. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
14. Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy.
Kim JY; Cho N; Jeyanth JX; Kim WH; Lee SH; Gweon HM; Moon WK
AJR Am J Roentgenol; 2014 Apr; 202(4):912-21. PubMed ID: 24660724
[TBL] [Abstract][Full Text] [Related]
15. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP
Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382
[TBL] [Abstract][Full Text] [Related]
16. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes.
Schvartsman G; Gutierrez-Barrera AM; Song J; Ueno NT; Peterson SK; Arun B
Cancer Med; 2017 Nov; 6(11):2515-2522. PubMed ID: 29024537
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
18. Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer.
van der Sangen MJ; Poortmans PM; Scheepers SW; Lemaire BM; van Berlo CL; Tjan-Heijnen VC; Voogd AC
Eur J Surg Oncol; 2013 Aug; 39(8):892-8. PubMed ID: 23726902
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer recurrences in elderly patients after lumpectomy.
Shah S; Doyle K; Lange EM; Shen P; Pennell T; Ferree C; Levine EA; Perrier ND
Am Surg; 2002 Aug; 68(8):735-9. PubMed ID: 12206612
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
Owusu C; Lash TL; Silliman RA
Breast J; 2007; 13(4):374-82. PubMed ID: 17593042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
